Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

FTC blocks John Muir’s California medical centre purchase

The FTC argues that the deal would lead to higher healthcare costs in the region.

November 20 2023

The Federal Trade Commission (FTC) in the US has lodged an antitrust lawsuit to block John Muir Health's planned $142.5m deal for taking full ownership in San Ramon Regional Medical Center from Tenet Healthcare.

The agency argues that the deal would eliminate competition between John Muir Health and San Ramon Regional Medical Center in California's I-680 corridor, leading to higher healthcare costs.

This complaint alleges that the acquisition would give John Muir Health control over more than 50% of the market for inpatient general acute care services in the region.

According to the agency, this would result in increased insurance premiums, co-pays, and other out-of-pocket costs for commercial health insurance enrollees.

The FTC and the California Attorney General's office are jointly filing a complaint in federal court and seeking a temporary restraining order to prevent the transaction pending an administrative proceeding.

This complaint asserts that the proposed deal would reduce incentives for quality improvements in healthcare services in the affected region.

FTC Bureau of Competition director Henry Liu said: “San Ramon Regional Medical Center has played an important role in ensuring Californians in the I-680 corridor have access to quality, affordable care for critical health care services, such as cardiac surgery and childbirth.

“John Muir’s acquisition of San Ramon Medical would increase already high health care costs in the area and threaten to stall quality improvements that help advance care for all patients.”

John Muir Health comprises two prominent medical centres, the Walnut Creek Medical Center and the Concord Medical Center.

Besides, it operates urgent care centres and provides primary care and outpatient services.

Its physician network includes more than 1,000 primary care and specialist physicians, and its medical group consists of 350 clinicians.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close